Dolat Capital: Cadila Healthcare Posts In-Line Q2, Vaccine Data Key Monitorable
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Cadila Healthcare Ltd. reported an in-line Q2 driven by strong growth across India, U.S. and the active pharmaceutical ingredient segment offsetting the muted growth in consumer segment.
Revenue grew 16% YoY, an improved product mix (double digit growth in India formulations and U.S. sales at $230 million, up $13 million QoQ) led to healthy gross margins at 64.9%.
Impact of Merchandise Exports from India Scheme offset lower marketing spends, thereby, restricting Ebitda margins at 22.6%.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.